Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The telehealth company Ro, which in the past offered compounded tirzepatide, in December announced it would be offering ...

Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

Zepbound is an injectable prescription medication created to help adults with obesity and weight-related problems, including obstructive sleep apnea. OSA causes airway collapses during sleep and ...

We recently published a list of 10 Best Blue Chip Stocks to Buy for 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best blue chip ...

He highlights the robust growth potential of Eli Lilly's drug Zepbound, which could become a $100 billion market opportunity. Dow plunges nearly 700 points in response to good economic news.

The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug Zepbound for obstructive sleep apnea, reported Annika Kim ...

Another top 10 holding is Eli Lilly, the pharma giant behind the Mounjaro and Zepbound obesity drugs. By the beginning of the next decade, global annual sales of these and other weight-loss drugs ...